Apalutamide Active in Castration - Resistant Prostate Cancer
Apalutamide prolongs metastasis - free survival in non - metastatic castration - resistant prostate cancer
Publication date: September–October 2018Source: Journal of the American Society of Cytopathology, Volume 7, Issue 5Author(s): Alexander Shtabsky, Keren Gueta-Milshtein, Jonathan Modai, Igal Shpunt, Yuval Avda, Yaniv Shilo, Uri Lindner, Dan Leibovici
A novel cross-talk between CXCR4 and PI4KIIIα in prostate cancer cellsA novel cross-talk between CXCR4 and PI4KIIIα in prostate cancer cells, Published online: 15 August 2018; doi:10.1038/s41388-018-0448-0A novel cross-talk between CXCR4 and PI4KIIIα in prostate cancer cells
Nataliya Mar, MD, UC Irvine Health, shares her Abstracts were Metastatic Genitourinary Malignancies | Mix of Urothelial Carcinoma, Prostate Cancer, &RCC at MOASC 2018 Author: moasc Added: 08/14/2018
Authors: Alexander W Abstract We review key findings in the areas of prostate cancer, non-small-cell lung cancer, breast cancer, esophageal cancer, pancreatic cancer, leukemias, metastatic colon cancer, and one session on molecular profiling guidance of therapy. PMID: 30100691 [PubMed]
DISCUSSION: This small, prospective case series suggests that, in the short term, HDR brachytherapy is safe and well tolerated in IBD patients. Therefore, IBD should not automatically disqualify patients from, at least, HDR brachytherapy. The reason why these results differ from previous LDR studies possibly reflects the benefit of inverse planning, which more readily achieves rectal dose constraints in HDR brachytherapy. PMID: 30099986 [PubMed - in process]
ConclusionsnmCRPC is a heterogeneous disease; while observation may be an option for some patients, enzalutamide and apalutamide may be appropriate to treat nmCRPC patients with PSA-DT ≤10 mo. The emergence of more accurate imaging modalities as well as circulating tumour biomarker assays will likely redefine the assessment of nmCRPC in the near future.Patient summaryHerein, we review key literature and clinical practice guidelines to summarise the optimal management of patients with prostate cancer and rising prostate-specific antigen despite castrate testosterone levels, but with no evidence of distant metastasis on t...
Authors: Cajigas-Du Ross CK, Martinez SR, Woods-Burnham L, Durán AM, Roy S, Basu A, Ramirez JA, Ortiz-Hernández GL, Ríos-Colón L, Chirshev E, Sanchez-Hernandez ES, Soto U, Greco C, Boucheix C, Chen X, Unternaehrer J, Wang C, Casiano CA Abstract Patients with metastatic castration-resistant prostate cancer (mCRPC) develop resistance to conventional therapies including docetaxel (DTX). Identifying molecular pathways underlying DTX resistance is critical for developing novel combinatorial therapies to prevent or reverse this resistance. To identify transcriptomic signatures associated with ...
Conclusions: Our results demonstrate that not all DNA repair alterations are equally predictive of PARP inhibitor response. Importantly, all responding patients had tumors harboring BRCA2 DNA repair alterations, including one without a known pathogenic mutation. Conversely, among the 4 nonresponders, several DNA repair alterations in genes other than BRCA2 were identified that were not clearly pathogenic. This demonstrates the need to carefully examine the functional relevance of the DNA repair alterations identified, especially in genes other than BRCA2, when considering patients for PARP inhibitor treatment. PMID: 30...
Dr Gerald Chodak discusses a long-term study demonstrating the efficacy of finasteride in preventing prostate cancer, as well as the questions it raises regarding clinical use.Medscape Urology
PROSTATE cancer risk could be lowered by losing weight or by avoiding pesticides, it ’s been claimed. But you could reveal your chances of developing prostate cancer symptoms by checking your fingers - this is what to look out for.